John Sundy
About John Sundy
John Sundy: Chief Medical Officer and Head of R&D
John Sundy serves as the Chief Medical Officer and Head of Research & Development. He brings over 25 years of experience in both academic medicine and the biotechnology industry, with an extensive background in rheumatology and immunology. Sundy previously held key leadership positions, such as Chief Medical Officer of Pandion Therapeutics, which was acquired by Merck for $1.85 billion, and Senior Vice President and Inflammation Therapeutic Area Head at Gilead Sciences. At Gilead, he led the company's entry into inflammation and immunology, overseeing the clinical development of over a dozen drug programs.
John Sundy's Education and Expertise
John Sundy completed his undergraduate education at Bucknell University and earned his medical and scientific education at Drexel University. He completed his residency and fellowship training at Duke University. Sundy is a fellow of several prestigious organizations, including the American College of Rheumatology, the American Academy of Allergy Asthma and Immunology, and the American College of Physicians. His research has primarily focused on developing novel therapies for inflammatory and fibrotic diseases.
John Sundy's Background in Rheumatology and Immunology
John Sundy holds clinical privileges in rheumatology at the Duke-affiliated Durham VA Medical Center and serves as an Adjunct Professor of Medicine at Duke University. He has a rich background in academic and clinical roles, including serving as a tenured Associate Professor of Medicine at Duke University and the Duke-National University of Singapore Graduate Medical School. Sundy has also been the Associate Director of the Duke Clinical Research Institute and directed Duke's Global Proof of Concept Research Unit Network.
John Sundy's Research and Publications
John Sundy has authored over 100 scientific publications and has significantly contributed to advancing medical knowledge in his field. His work in drug development includes leading the Phase 1-3 development of Krystexxa for refractory gout and the approval of Jyselica in Europe and Japan for rheumatoid arthritis and ulcerative colitis. Sundy's research career is marked by his innovation in creating therapies for inflammatory and fibrotic diseases, demonstrating his commitment to improving patient care.
John Sundy on the Board of Directors of CARRA
John Sundy serves on the board of directors of the Childhood Arthritis and Rheumatology Research Alliance (CARRA). His role involves contributing to the organization's mission to advance research and improve the lives of children with arthritis and rheumatic diseases. Sundy's extensive experience in clinical research and his leadership in drug development provide valuable insights to the board, supporting CARRA's strategic initiatives.